Foghorn Therapeutics cuts workforce by roughly 40% after Eli Lilly ends cancer partnership

Oct 2, 2026 13:50 (22d ago)

Verifying

Foghorn Therapeutics is reducing its workforce after Eli Lilly ended a cancer drug partnership.
Foghorn plans to cut roughly 40% of its workforce.
The Massachusetts-based biotech is redirecting resources toward its own pipeline programs.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.